|
|
|
Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant |
Hao Wang, Li Liu, Tangchun Wu( ) |
| Ministry of Education and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China |
|
|
|
|
|
|
Corresponding Author(s):
Tangchun Wu
|
|
Just Accepted Date: 23 May 2023
Online First Date: 27 June 2023
Issue Date: 28 July 2023
|
|
| 1 |
A Pan, L Liu, C Wang, H Guo, X Hao, Q Wang, J Huang, N He, H Yu, X Lin, S Wei, T Wu. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA 2020; 323(19): 1915–1923
https://doi.org/10.1001/jama.2020.6130
pmid: 32275295
|
| 2 |
One World in Data. Coronavirus (COVID-19) Vaccinations, England. 2022
|
| 3 |
OJ Watson, G Barnsley, J Toor, AB Hogan, P Winskill, AC Ghani. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022; 22(9): 1293–1302
https://doi.org/10.1016/S1473-3099(22)00320-6
pmid: 35753318
|
| 4 |
SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland, BK Ackerson, H Takhar, OA Ogun, S Simmons, JM Zamparo, L Jodar, JM McLaughlin. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis 2022; 22(12): 1663–1665
https://doi.org/10.1016/S1473-3099(22)00692-2
pmid: 36306800
|
| 5 |
N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, C Gower, M Kall, N Groves, AM O’Connell, D Simons, PB Blomquist, A Zaidi, S Nash, Binti Abdul Aziz N Iwani, S Thelwall, G Dabrera, R Myers, G Amirthalingam, S Gharbia, JC Barrett, R Elson, SN Ladhani, N Ferguson, M Zambon, CNJ Campbell, K Brown, S Hopkins, M Chand, M Ramsay, Bernal J Lopez. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532–1546
https://doi.org/10.1056/NEJMoa2119451
pmid: 35249272
|
| 6 |
Z Huang, S Xu, J Liu, L Wu, J Qiu, N Wang, J Ren, Z Li, X Guo, F Tao, J Chen, D Lu, X Sun, W Wang. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 2022; 20(1): 400
https://doi.org/10.1186/s12916-022-02606-8
pmid: 36266697
|
| 7 |
DY Lin, Y Gu, Y Xu, B Wheeler, H Young, SK Sunny, Z Moore, D Zeng. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022; 328(14): 1415–1426
https://doi.org/10.1001/jama.2022.17876
pmid: 36155617
|
| 8 |
S Mallapaty. China’s COVID vaccines have been crucial—now immunity is waning. Nature 2021; 598(7881): 398–399
https://doi.org/10.1038/d41586-021-02796-w
pmid: 34650240
|
| 9 |
Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Sci Adv 2021; 7(6): eabf1374 doi:10.1126/sciadv.abf1374
pmid: 33536223
|
| 10 |
SB Omer, PN Malani. Booster vaccination to prevent COVID-19 in the era of Omicron: an effective part of a layered public health approach. JAMA 2022; 327(7): 628–629
https://doi.org/10.1001/jama.2022.0892
pmid: 35061011
|
| 11 |
World Health Organization. COVID-19 vaccination roll-out stagnates in Africa. 2022
|
| 12 |
Central People’s Government of the People’s Republic of China. The press conference for the control and prevention of COVID-19 Epidemic, China. 2021
|
| 13 |
FC Zhu, XH Guan, YH Li, JY Huang, T Jiang, LH Hou, JX Li, BF Yang, L Wang, WJ Wang, SP Wu, Z Wang, XH Wu, JJ Xu, Z Zhang, SY Jia, BS Wang, Y Hu, JJ Liu, J Zhang, XA Qian, Q Li, HX Pan, HD Jiang, P Deng, JB Gou, XW Wang, XH Wang, W Chen. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249): 479–488
https://doi.org/10.1016/S0140-6736(20)31605-6
pmid: 32702299
|
| 14 |
Z FuD LiangW ZhangD ShiY MaD WeiJ XiS YangX XuD TianZ ZhuM GuoL JiangS YuS WangF JiangY LingS WangS ChenF LiuY TanX Fan. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front Med 2023; [Epub ahead of print] doi:
https://doi.org/10.1007/s11684-022-0977-3
pmid: 36949347
|
| 15 |
Y Gao, T Li, M Han, X Li, D Wu, Y Xu, Y Zhu, Y Liu, X Wang, L Wang. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92(7): 791–796
https://doi.org/10.1002/jmv.25770
pmid: 32181911
|
| 16 |
JJ Zhang, YY Cao, G Tan, X Dong, BC Wang, J Lin, YQ Yan, GH Liu, M Akdis, CA Akdis, YD Gao. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2021; 76(2): 533–550
https://doi.org/10.1111/all.14496
pmid: 32662525
|
| 17 |
C Zheng, W Shao, X Chen, B Zhang, G Wang, W Zhang. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022; 114: 252–260
https://doi.org/10.1016/j.ijid.2021.11.009
pmid: 34800687
|
| 18 |
P Nordström, M Ballin, A Nordström. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022; 399(10327): 814–823
https://doi.org/10.1016/S0140-6736(22)00089-7
pmid: 35131043
|
| 19 |
P Adab, S Haroon, ME O’Hara, RE Jordan. Comorbidities and covid-19. BMJ 2022; 377: o1431
https://doi.org/10.1136/bmj.o1431
pmid: 35705219
|
| 20 |
L Kompaniyets, AF Pennington, AB Goodman, HG Rosenblum, B Belay, JY Ko, JR Chevinsky, LZ Schieber, AD Summers, AM Lavery, LE Preston, ML Danielson, Z Cui, G Namulanda, H Yusuf, WR Mac Kenzie, KK Wong, J Baggs, TK Boehmer, AV Gundlapalli. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis 2021; 18: 210123
https://doi.org/10.5888/pcd18.210123
pmid: 34197283
|
| 21 |
World Health Organization. COVID-19 vaccines technical documents. 2021
|
| 22 |
A Utami, A Margawati, D Pramono, A Nugraheni, SG Pramudo. Determinant factors of COVID-19 vaccine hesitancy among adult and elderly population in Central Java, Indonesia. Patient Prefer Adherence 2022; 16: 1559–1570
https://doi.org/10.2147/PPA.S365663
pmid: 35789823
|
| 23 |
WS Choi, HJ Cheong. COVID-19 vaccination for people with comorbidities. Infect Chemother 2021; 53(1): 155–158
https://doi.org/10.3947/ic.2021.0302
pmid: 34409789
|
| 24 |
R Tsai, J Hervey, K Hoffman, J Wood, J Johnson, D Deighton, D Clermont, B Loew, SL Goldberg. COVID-19 vaccine hesitancy and acceptance among individuals with cancer, autoimmune diseases, or other serious comorbid conditions: cross-sectional, internet-based survey. JMIR Public Health Surveill 2022; 8(1): e29872
https://doi.org/10.2196/29872
pmid: 34709184
|
| 25 |
H Chung, S He, S Nasreen, ME Sundaram, SA Buchan, SE Wilson, B Chen, A Calzavara, DB Fell, PC Austin, K Wilson, KL Schwartz, KA Brown, JB Gubbay, NE Basta, SM Mahmud, CH Righolt, LW Svenson, SE MacDonald, NZ Janjua, M Tadrous, JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators Kwong. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021; 374: n1943
https://doi.org/10.1136/bmj.n1943
pmid: 34417165
|
| 26 |
A Paternina-Caicedo, M Jit, N Alvis-Guzmán, JC Fernández, J Hernández, JJ Paz-Wilches, J Rojas-Suarez, C Dueñas-Castell, NJ Alvis-Zakzuk, AD Smith, F Hoz-Restrepo. Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Reg Health Am 2022; 12: 100296
https://doi.org/10.1016/j.lana.2022.100296
pmid: 35791428
|
| 27 |
G Lu, Y Zhang, H Zhang, J Ai, L He, X Yuan, S Bao, X Chen, H Wang, J Cai, S Wang, W Zhang, J Xu. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg Microbes Infect 2022; 11(1): 2045–2054
https://doi.org/10.1080/22221751.2022.2109517
pmid: 35924388
|
| 28 |
L Coppeta, O Balbi, Z Grattagliano, GG Mina, A Pietroiusti, A Magrini, M Bolcato, M Trabucco Aurilio. First dose of the BNT162b2 mRNA COVID-19 vaccine reduces symptom duration and viral clearance in healthcare workers. Vaccines (Basel) 2021; 9(6): 659
https://doi.org/10.3390/vaccines9060659
pmid: 34204252
|
| 29 |
Hopkins University COVID-19 Resource Center Johns. COVID-19 dashboard by the center for systems science and engineering at Johns Hopkins University, the USA. 2022
|
| 30 |
JRC Pulliam, C van Schalkwyk, N Govender, A von Gottberg, C Cohen, MJ Groome, J Dushoff, K Mlisana, H Moultrie. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593): eabn4947
https://doi.org/10.1126/science.abn4947
pmid: 35289632
|
| 31 |
E Eythorsson, HL Runolfsdottir, RF Ingvarsson, MI Sigurdsson, R Palsson. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open 2022; 5(8): e2225320
https://doi.org/10.1001/jamanetworkopen.2022.25320
pmid: 35921113
|
| 32 |
AA Mensah, J Lacy, J Stowe, G Seghezzo, R Sachdeva, R Simmons, A Bukasa, S O’Boyle, N Andrews, M Ramsay, H Campbell, K Brown. Disease severity during SARS-CoV-2 reinfection: a nationwide study. J Infect 2022; 84(4): 542–550
https://doi.org/10.1016/j.jinf.2022.01.012
pmid: 35085659
|
| 33 |
S Medić, C Anastassopoulou, Z Lozanov-Crvenković, V Vuković, N Dragnić, V Petrović, M Ristić, T Pustahija, Z Gojković, A Tsakris, JPA Ioannidis. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: a population-level observational study. Lancet Reg Health Eur 2022; 20: 100453
https://doi.org/10.1016/j.lanepe.2022.100453
pmid: 35791336
|
| 34 |
H WangY YuanB WuM XiaoZ WangT DiaoR ZengL ChenY LeiP LongY GuoX LaiY WenW LiH CaiL SongW NiY ZhaoK OuyangJ WangQ WangL LiuC WangA PanX LiR GongT Wu. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Front Med 2023; [Epub ahead of print] doi:
https://doi.org/10.1007/s11684-022-0954-x
pmid: 36738428
|
| 35 |
JM Carreño, H Alshammary, J Tcheou, G Singh, AJ Raskin, H Kawabata, LA Sominsky, JJ Clark, DC Adelsberg, DA Bielak, AS Gonzalez-Reiche, N Dambrauskas, V; PSP-PARIS Study Group; Srivastava K Vigdorovich, DN Sather, EM Sordillo, G Bajic, Bakel H van, V Simon, F Krammer. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022; 602(7898): 682–688
https://doi.org/10.1038/s41586-022-04399-5
pmid: 35016197
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
